Beam, Inc. (BEAM) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/14/2026

1. ERAS
2. SPRO
3. TREX
4. AAPL
5. NFLX
6. SPY
7. HCLT:IN
8. KKR
9. IBM
10. JPM

Go back to Beam, Inc. (BEAM) Tops Q3 EPS by 1c

JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)

November 5, 2024 2:56 PM EST

JPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst comments "Key updates alongside 3Q results (loss per share of $1.17) centered on the companys SCD/B-thal cell therapy franchise ahead of multiple presentations at... More

Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'

November 5, 2024 11:47 AM EST

Stifel analyst Benjamin Burnett reiterated a Buy rating and $69.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)

The analyst comments "As expected from an initial update from a lead program, early BEAM-101 (sickle cell disease [SCD]) disclosure offers important takeaways that, understandably, trigger investor... More

BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'

November 5, 2024 8:58 AM EST

BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $57.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst comments "The first-ever clinical data from BEAM's base editing platform in SCD demonstrate a robust BEAM-101 efficacy/safety profile with differentiating characteristics compared... More